JKHY — Jack Henry & Associates, Inc.

The market turned positive after the August 18, 2026 Q4 print: EPS of $1.57 beat consensus by $0.13, FY27 guidance came in above expectations, and analysts raised targets (Wolfe to $215, D.A. Davidson to $198). Sentiment is supported by 58 competitive core wins, 47% faster-payments revenue growth, and a 13 Buy / 10 Hold / 0 Sell consensus. The only caution is that the stock has already rallied ~8% post-earnings and RSI is at 65.

Revenue has marched steadily higher over three years, from $538M-$571M quarterly in FY2024 to $619M-$645M in FY2026; full-year FY26 revenue rose about 6.7% to $2.53B. The trend inflected modestly lower at the margin: Q4 FY26 GAAP revenue grew only 2.9% YoY to $633.1M (vs ~9.9% YoY in Q4 FY25) and GAAP operating income fell 14.8% YoY, with operating margin down to 21.0% from 25.3%. That looks like a quarter-specific dip — full-year FY26 operating margin expanded to 24.9% from 23.9%, and management says non-GAAP margins rose 92bps — but it is a real deceleration to watch. Free cash flow was much healthier: TTM FCF rose ~18% to $694.9M, and operating cash flow exceeded net income (accruals ratio -6.1%).

The stock is cheap relative to its own history but not cheap in absolute terms. As of 2026-08-27, trailing P/E was 24.3x vs a 5-year average of 29.9x, and P/S was 4.76x vs a 5-year average of 5.5x. On FY27 consensus EPS of $7.346, the forward P/E is about 23.1x. For a mid-single-digit grower with 24.9% operating margins, that is a fair-to-slightly-attractive price; it is not the bargain the historical multiple gap alone implies.

At 23x forward earnings, JKHY is pricing in steady mid-single-digit growth and stable margins, not a major acceleration. If FY27 margin expansion of 20-40bps and EPS of $7.33-$7.38 are delivered, the stock should re-rate toward $187-$190. If Q4 FY26's GAAP margin compression turns out to be the start of a structural cost problem, a de-rate to 20x forward EPS would put the stock near $147. The market is paying for quality and recurring revenue, but not extrapolating the FY26 Q4 weakness.

As of 2026-08-27, RSI was 65.09, price was $169.64, +6.42% above the 20-day, +12.99% above the 50-day, and +6.13% above the 200-day. The stock is in a short-term uptrend following the earnings beat, but RSI is approaching overbought and the stock is 12-13% above its 50-day, so chasing here is less attractive; a pullback toward the 50-day near $150 would offer a better risk/reward entry.

• Persistent interest-rate volatility and tighter net interest margins keep pressure on community-bank technology budgets, but also push banks toward efficiency-driving modernization.
• Banking-sector M&A creates deconversion revenue ($42.8M in FY26) but also reduces the long-term client base; management strips this out of non-GAAP core tracking.
• Secular shift to real-time/faster payments is a tailwind — faster-payments revenue grew 47% YoY.
• AI-embedded fraud, compliance, and financial-crimes tools are becoming must-buys for smaller institutions, supporting new client wins.
• Cloud migration and core-system replacement cycles provide a multi-year revenue backdrop, though the pace is gradual rather than explosive.

• Q1 FY27 earnings (late Oct/early Nov 2026): first checkpoint on whether core wins convert to revenue and whether 20-40bps margin guidance is tracking.
• Faster-payments and AI adoption metrics: continued 40%+ growth in faster-payments revenue and AI suite wins would support re-rating.
• Deconversion and competitive core wins: 58 wins in FY26 shows share gains vs legacy providers; more large wins would extend the growth runway.
• Further analyst price-target increases following the post-earnings revisions.

• Q4 FY26 GAAP operating margin fell to 21.0% from 25.3% YoY — if repeated, the earnings trajectory is weaker than the headline FY27 guide implies.
• Bank consolidation reduces the number of small banks/credit unions, structurally shrinking the addressable market over time.
• Mid-single-digit organic growth may not justify a return to the 5-year average P/E of 29.9x; the stock is not cheap on forward earnings.
• Valuation already reflects a quality premium; any macro slowdown or technology-spending freeze could compress the multiple.

JKHY is a high-quality, conservatively financed compounder — low debt, ~1.7% dividend yield, strong FCF conversion, and a sticky recurring-revenue base — but the current price is roughly in line with fair value. The FY27 guide supports moderate upside to around $187, while the recent Q4 GAAP margin dip and mid-single-digit growth cap the near-term return; this is a hold/accumulate-on-weakness rather than an urgent buy.

Calculated by applying a 25.5x forward multiple to FY2027 consensus EPS of $7.346 — a discount to the 5-year average P/E of 29.9x to reflect mid-single-digit growth, but a premium to the current 23x to reflect recurring revenue, low leverage, and strong FCF conversion. A cross-check using ~5.0x FY27 revenue (vs 5.5x 5-year average) lands near $188, so $187.32 is a reasonable intrinsic estimate.